Cytomos Unveiled Predictive Cell Platform
The new AuraCyt platform uses dielectric spectroscopy to identify CAR T cell signatures during manufacturing.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you believe new diagnostic technologies will make life-saving medical treatments more affordable for patients?
Cytomos has launched the AuraCyt platform to improve CAR T therapy manufacturing through predictive cell intelligence. A new case study shows the platform can identify cell population changes two days earlier than traditional methods.
Why it matters
Manufacturing life-saving CAR T therapies is often hindered by donor variability and lengthy, complex workflows. AuraCyt aims to resolve these constraints by shifting quality control from retrospective analysis to real-time predictive processing.
The AuraCyt platform uses ultra-wideband dielectric spectroscopy to measure frequency-dependent electrical behavior. This process generates 507 unique parameters per cell to establish high-dimensional digital fingerprints.
The players
Cytomos
Cytomos is a biotechnology company that specializes in developing cell analysis platforms for the life sciences industry.
The details
By measuring 200 frequencies per cell, the system detects structural changes before they are visible through conventional assessment. In an eight-day workflow study, the technology successfully tracked T-cell development from baseline to maturity.
Timeline
Day 0: Baseline analysis of donor T cells was performed.
Day 4: AuraCyt detected initial divergence in cell populations.
Day 6: Flow cytometry confirmed CAR-CD34 expression.
Day 8: The manufacturing workflow study concluded.
The Tech Race
This development follows a pattern set by the seven FDA-approved CAR T therapies, providing the technological infrastructure to scale production for these established treatments. It represents a significant evolution from retrospective quality assessment toward proactive process control.
The platform provides biotech manufacturers with granular, real-time data to optimize cell production efficiency. These improvements could eventually accelerate the manufacturing cycle for specialized therapies, potentially reducing wait times for patients.
The takeaway
Predictive platforms are increasingly vital for managing the complexities of personalized medicine. Adopting real-time cellular monitoring allows developers to catch deviations early, ensuring more consistent outcomes in high-stakes biotech manufacturing.
Further reading
For more information on innovations in the field, explore the Biotech section.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Do you believe new diagnostic technologies will make life-saving medical treatments more affordable for patients?
